NCT02514447 2025-09-25
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
G1 Therapeutics, Inc.
Phase 1/2 Completed
Clinical Trials
10 trialsNCT03041311 2025-09-25
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
G1 Therapeutics, Inc.
Phase 2 Completed
NCT04887831 2025-09-08
PRESERVE3
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT05113966 2025-01-29
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT04607668 2024-11-26
PRESERVE1
G1 Therapeutics, Inc.
Phase 3 Terminated
NCT04902885 2024-07-10
Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT05112536 2024-03-12
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
G1 Therapeutics, Inc.
Phase 2 Completed
NCT04863248 2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT02978716 2022-03-23
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT02499770 2020-08-21
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
G1 Therapeutics, Inc.
Phase 1/2 Completed